Brain aging once looked like a one-way march. Chronic low-grade inflammation settles in the hippocampus. Microglia cluster and turn hostile. Mitochondria falter. Memory slips. Doctors accepted it as inevitable.
But a team at Texas A&M University has shown otherwise. In aged mice, two doses of a nasal spray carrying human neural stem cell-derived extracellular vesicles reversed key signs of that decline. Inflammation dropped. Cellular energy plants revived. Memory sharpened. The effects held for months.
Targeting Neuroinflammaging at Its Source
The spray delivers tiny vesicles packed with specific microRNAs. These parcels slip past the blood-brain barrier through the olfactory pathway. They home in on overactive microglia. Once inside, the microRNAs act as master regulators. They dial down the NLRP3 inflammasome and the cGAS-STING signaling cascade that fuels type 1 interferon responses.
Single-cell RNA sequencing captured the shift. Seven days after treatment, microglial transcriptomes showed widespread reprogramming. Proinflammatory genes fell silent. Genes tied to oxidative phosphorylation rose. Astrocyte hypertrophy eased. Oxidative stress markers declined while antioxidant proteins climbed. Mitochondria regained function. Neurons got their spark back.
“Brain age-related diseases like dementia are a major health concern worldwide,” said Dr. Ashok K. Shetty, university distinguished professor and associate director of the Institute for Regenerative Medicine at Texas A&M’s Naresh K. Vashisht College of Medicine. “What we’re showing is brain aging can be reversed, to help people stay mentally sharp, socially engaged and free from age-related decline.” (Texas A&M Stories)
The study used late-middle-aged mice, 18 months old at the start. Treatment came at 20.5 months. Behavioral tests followed. Treated animals outperformed controls in object recognition and location tasks. They noticed novelty faster. They adapted better. Results held across males and females. “It’s universal,” Shetty noted. “Treatment outcomes were consistent and similar across both sexes.”
Dr. Madhu Leelavathi Narayana, senior research scientist, zeroed in on the mitochondria. “We are giving neurons their spark back by reducing oxidative stress and reactivating the brain’s mitochondria.” In vitro work pinpointed two key microRNAs: miRNA-30e-3p and miRNA-181a-5p. They directly inhibit NLRP3 and STING pathways.
Dr. Maheedhar Kodali, another senior research scientist on the team, highlighted delivery. “The mode of delivery is one of the most exciting aspects of our approach. Intranasal delivery allows us to reach, and treat, the brain directly without invasive procedures.” (ScienceDaily)
These findings build on decades of work linking neuroinflammaging to cognitive decline. For years scientists viewed the process as irreversible. Chronic activation of immune cells in the brain slowly erodes synaptic function and neuronal health. Standard approaches often focused on symptom management or broad anti-inflammatory drugs with limited brain penetration and side effects.
This vesicle therapy takes a different route. The extracellular vesicles come from human induced pluripotent stem cell-derived neural stem cells. They carry a natural cargo evolved for cell-to-cell communication. No viral vectors. No surgery. Just two sprays. And the benefits persisted. Memory gains lasted months in the preclinical models.
Shetty sees broader promise. “As we develop and scale this therapy, a simple, two-dose nasal spray could one day replace invasive, risky procedures or maybe even months of medication.” He added, “We are seeing the brain’s own repair systems switch on, healing inflammation and restoring itself.” (Neuroscience News)
The paper appeared in the Journal of Extracellular Vesicles. Titled “Intranasal Human NSC-Derived EVs Therapy Can Restrain Inflammatory Microglial Transcriptome, and NLRP3 and cGAS-STING Signalling, in Aged Hippocampus,” it provides open-access detail on the molecular reprogramming. Texas A&M has filed a U.S. patent. Human trials remain ahead. Yet the preclinical data already stand out for their depth. Few studies combine behavioral rescue, detailed pathway analysis, single-cell sequencing and long-term follow-up in one package.
Other recent coverage echoes the excitement while urging caution. A review in EMJ noted the reduction in astrocyte hypertrophy, microglial clustering and oxidative stress alongside increased mitochondrial gene expression. It suggested the approach could slow progression in Alzheimer’s or aid stroke recovery. Still, translation from mice to people will demand years of safety and dosing work. (EMJ Reviews, April 21, 2026)
But the core message lands hard. Brain aging need not be accepted as fixed. Inflammation once thought permanent can be quieted. Mitochondrial failure can be reversed. Memory circuits can wake up again. All from a nasal spray.
Shetty put it plainly. “Our approach redefines what it means to grow old. We’re aiming for successful brain aging: keeping people mentally sharp and connected. Not just living longer, but living smarter and healthier.”
That vision now has experimental backing. The next steps will test whether the same vesicles deliver in human brains burdened by decades of accumulated damage. If they do, medicine may gain a powerful, noninvasive tool against one of aging’s most feared costs.
WebProNews is an iEntry Publication